<?xml version='1.0' encoding='utf-8'?>
<document id="31256150"><sentence text="Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia."><entity charOffset="0-13" id="DDI-PubMed.31256150.s1.e0" text="Phenobarbital" /><entity charOffset="15-24" id="DDI-PubMed.31256150.s1.e1" text="Midazolam" /><pair ddi="false" e1="DDI-PubMed.31256150.s1.e0" e2="DDI-PubMed.31256150.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31256150.s1.e0" e2="DDI-PubMed.31256150.s1.e1" /></sentence><sentence text="Phenobarbital and midazolam are commonly used drugs in (near-)term neonates treated with therapeutic hypothermia for hypoxic-ischaemic encephalopathy, for sedation, and/or as anti-epileptic drug"><entity charOffset="18-27" id="DDI-PubMed.31256150.s2.e0" text="midazolam" /></sentence><sentence text=" Phenobarbital is an inducer of cytochrome P450 (CYP) 3A, while midazolam is a CYP3A substrate" /><sentence text=" Therefore, co-treatment with phenobarbital might impact midazolam clearance"><entity charOffset="30-43" id="DDI-PubMed.31256150.s4.e0" text="phenobarbital" /><entity charOffset="57-66" id="DDI-PubMed.31256150.s4.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.31256150.s4.e0" e2="DDI-PubMed.31256150.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31256150.s4.e0" e2="DDI-PubMed.31256150.s4.e1" /></sentence><sentence text="" /><sentence text="To assess pharmacokinetics and clinical anti-epileptic effectiveness of phenobarbital and midazolam in asphyxiated neonates and to develop dosing guidelines"><entity charOffset="90-99" id="DDI-PubMed.31256150.s6.e0" text="midazolam" /></sentence><sentence text="" /><sentence text="Data were collected in the prospective multicentre PharmaCool study" /><sentence text=" In the present study, neonates treated with therapeutic hypothermia and receiving midazolam and/or phenobarbital were included"><entity charOffset="83-92" id="DDI-PubMed.31256150.s9.e0" text="midazolam" /><entity charOffset="100-113" id="DDI-PubMed.31256150.s9.e1" text="phenobarbital" /><pair ddi="false" e1="DDI-PubMed.31256150.s9.e0" e2="DDI-PubMed.31256150.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31256150.s9.e0" e2="DDI-PubMed.31256150.s9.e1" /></sentence><sentence text=" Plasma concentrations of phenobarbital and midazolam including its metabolites were determined in blood samples drawn on days 2-5 after birth"><entity charOffset="26-39" id="DDI-PubMed.31256150.s10.e0" text="phenobarbital" /><entity charOffset="44-53" id="DDI-PubMed.31256150.s10.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.31256150.s10.e0" e2="DDI-PubMed.31256150.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31256150.s10.e0" e2="DDI-PubMed.31256150.s10.e1" /></sentence><sentence text=" Pharmacokinetic analyses were performed using non-linear mixed effects modelling; clinical effectiveness was defined as no use of additional anti-epileptic drugs" /><sentence text="" /><sentence text="Data were available from 113 (phenobarbital) and 118 (midazolam) neonates; 68 were treated with both medications" /><sentence text=" Only clearance of 1-hydroxy midazolam was influenced by hypothermia"><entity charOffset="19-38" id="DDI-PubMed.31256150.s14.e0" text="1-hydroxy midazolam" /></sentence><sentence text=" Phenobarbital co-administration increased midazolam clearance by a factor 2"><entity charOffset="43-52" id="DDI-PubMed.31256150.s15.e0" text="midazolam" /></sentence><sentence text="3 (95% CI 1" /><sentence text="9-2" /><sentence text="9, p &lt; 0" /><sentence text="05)" /><sentence text=" Anticonvulsant effectiveness was 65" /><sentence text="5% for phenobarbital and 37"><entity charOffset="7-20" id="DDI-PubMed.31256150.s21.e0" text="phenobarbital" /></sentence><sentence text="1% for add-on midazolam"><entity charOffset="14-23" id="DDI-PubMed.31256150.s22.e0" text="midazolam" /></sentence><sentence text="" /><sentence text="Therapeutic hypothermia does not influence clearance of phenobarbital or midazolam in (near-)term neonates with hypoxic-ischaemic encephalopathy"><entity charOffset="56-69" id="DDI-PubMed.31256150.s24.e0" text="phenobarbital" /><entity charOffset="73-82" id="DDI-PubMed.31256150.s24.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.31256150.s24.e0" e2="DDI-PubMed.31256150.s24.e0" /><pair ddi="false" e1="DDI-PubMed.31256150.s24.e0" e2="DDI-PubMed.31256150.s24.e1" /></sentence><sentence text=" A phenobarbital dose of 30 mg/kg is advised to reach therapeutic concentrations"><entity charOffset="3-16" id="DDI-PubMed.31256150.s25.e0" text="phenobarbital" /></sentence><sentence text=" Phenobarbital co-administration significantly increased midazolam clearance"><entity charOffset="57-66" id="DDI-PubMed.31256150.s26.e0" text="midazolam" /></sentence><sentence text=" Should phenobarbital be substituted by non-CYP3A inducers as first-line anticonvulsant, a 50% lower midazolam maintenance dose might be appropriate to avoid excessive exposure during the first days after birth" /><sentence text="" /></document>